Early prediction of treatment outcome in head and neck cancer with 2-18FDG PET
Early prediction of treatment outcome in head and neck cancer with 2-18FDG PET
复制标题
DOI：
10.3109/02841869709001348
复制
发表时间：
1997-01-01
期刊：
影响因子：
3.1
通讯作者：
Strand, SE
中科院分区：
文献类型：
--
作者：
Brun, E;Ohlsson, T;Strand, SE
临床肿瘤学中替代治疗方案的发展增加了对癌症治疗结果的早期预测的需求。本研究的目的是，在治疗阶段的早期，识别晚期头颈癌患者，对启动治疗有反应或无反应。用2-（18）FDG-PET测定17例患者放疗（16-35戈伊）或联合化疗1个疗程前后的肿瘤葡萄糖代谢率（MRgl）。代谢值-吸收值归一化为血浆活性积分-与局部区域的结果相关，在治疗完成后5-6周进行评价。低肿瘤MRgl初始（
The development of alternative treatment regimens in clinical oncology has increased the need for early prediction of cancer therapy outcome. The aim of this study was, early in the treatment phase, to identify patients with advanced head and neck cancer, responding or not responding to initiated therapy. The tumour metabolic rate of glucose (MRgl) examined by 2-(18)FDG-PET was determined in 17 patients before and after the first weeks of either radiotherapy (16-35 Gy) or one course of combination chemotherapy. Metabolic values-uptake values normalized to plasma activity integrals-were correlated to loco-regional outcome, as evaluated 5-6 weeks after completion of treatment. Initial low tumour MRgl (